Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of a Measles Virus Derivative Producing CEA (MV-CEA) in Patients With Recurrent Glioblastoma Multiforme (GBM)

NCT00390299 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00390299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00390299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of a Measles Virus Derivative Producing CEA (MV-CEA) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
October 23, 2006
Completion date
November 30, 2019
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic oligodendroglioma, mixed glioma, recurrent glioblastoma